5HT1F- and 5HT7-receptor agonists for the treatment of migraines

CNS and Neurological Disorders - Drug Targets

Volumn 6, Issue 4, 2007, Pages 235-237

  Agosti, Reto M ^a  

^a Headache Centre Zurich Hirslanden   (Switzerland)

Author keywords

5 HT1B; 5 HT1D receptors; Anti migraine drugs; LY334370; mRNA

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ANTIMIGRAINE AGENT; LY 397584; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; NEUROTRANSMITTER; PLACEBO; RIZATRIPTAN; SB 656104A; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 1F RECEPTOR AGONIST; SEROTONIN 7 RECEPTOR AGONIST; SEROTONIN AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANXIETY; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE MODEL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; MIGRAINE; NONHUMAN; PROTEIN LOCALIZATION; RECEPTOR INTRINSIC ACTIVITY; SIDE EFFECT; SOMNOLENCE; TISSUE DISTRIBUTION; VASOCONSTRICTION; WEAKNESS;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; MIGRAINE DISORDERS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS;

EID: 34547731885     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152707781387242     Document Type: Article

References (51)

1. Wolff, H.G. Headache and other headache pain. Oxford University Press, 1963.
2. Ostfeld, A. M. Angiology, 1959, 10, 34-42.
3. Kimball, R.W., Friedman, A.P., Vallejo, E. Neurology(Minn), 1960, 10,107-111.
4. Anthony, M., Hinterberger, H., Lance, L.W. Res. Clin. Stud. Headache, 1969, 2, 29-59.
5. Humphrey, P.P., Feniuk, W., Perron, M.J., Connor, H.E., Oxford, A.W., Coates, L.H., Butina, D. Br. J. Pharmacol., 1988, 94, 1123-32.
6. Alexander, S.P.H., Peters, J.A. Trends Pharmacol. Sci., 1997; suppl.
7. Peroutka, S.J., McCarthy, B.G. Eur. J. Pharmacol., 1989, 163, 133-6.
8. Deliganis, A.V., Peroutka, S.K. Headache, 1991, 336, 228-31.
9. Edvinsson, L., Uddman, E., Wackenfors, A., Davenport A., Longmore, J., Malmsjo, M. Clin. Sci. (Lond), 2005, 109, 335-42.
10. Wackenfors, A., Jarvius, M., Ingemansson, R., Edvinsson, L., Malmsjo, M. J. Cardiovasc. Pharmacol., 2005, 45, 476-84.
11. Hamel, E., Gregoire, L., Lau, B. Eur. J. Pharmacol., 1993, 242, 75-82.
12. Bouchelet, I., Cohen, Z., Casse, B., Seguela, P., Hamel, E. J. Pharmacol. Exp. Ther., 1996, 50, 219-23.
13. Longmore, J., Shaw, D., Smith, D., Hopkins, R., McAllister, G., Pickard, J.D., Sirinathsinghji, D.J., Butler, A.J. Cephalalgia, 1997, 17, 833-842.
14. Rebeck, G.W., Maynard, K.I., Hyman, B.T., Moskowitz, M.A. Proc. Natl. Acad. Sci. USA, 1991, 91, 3666-3669.
15. Cutrer, F.M., Yu, X.J., Ayata, G., Moskowitz, M.A., Waeber, C. Neuropharmacology, 1999, 38, 1043-53.
16. Yu, X.J., Cutrer, F.M., Moskowitz, M.A., Waeber, C. Neuropharmacology, 1997, 36, 83-91.
17. Roon, K.I., Olesen, J., Diener, H.C., Ellis, P., Hettiarachchi, J., Poole, P.H., Christianssen, I., Kleinermans, D., Kok, J.G., Ferrari, M.D. Ann. Neurol., 2000, 47, 238-41.
18. Adham, N., Kao, N.T., Schecter, L.E., Bard, J., Olsen, M., Urquhart, D. Durkin, M., Hartig, P.R., Weinshank, R.L., Branchek, T.A. Proc. Natl. Acad. Sci. USA, 1993, 90, 408-12.
19. Johnson, K.W., Schaus, J.M., Durkin, M.M., Audia, J.E., Kaldor, S.W., Flaugh, M.E., Adham, N., Zgombick, J.M., Cohen, M.L., Branchek, A., Phebus, L.A. NeuroReport, 1997, 8, 2237-2240.
20. Adham, N., Bard, J.A., Zgombick, J.M., Durkin, M.M., Kucharewicz, S., Weinshank, R.L., Branchek, T.A. Neuropharmacology, 1997, 36, 569-76.
21. Bruinvels, A.T., Landwehrmeyer, B., Gustafson, E.L., Durkin, M.M., Mengod, G., Branchek, T.A., Hoyer, D., Palacios, J.M. Neuropharmacology, 1994, 33, 367-86.
22. Waeber, C., Moskowitz, M.A. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 352, 263-75.
23. Castro, M.E., Pascual, J., Romon, T., del Arco, C., del Olmo, E., Pazos, A. Neuropharmacology, 1997, 36, 535-42.
24. Pascual, J., Del Arco, C., Romon, T., Del Olmo, E., Pazos, A. Eur. J. Pharmacol. 1996, 29, 271-4.
25. Bouchelet, I., Case, B., Olivier, A., Hamel, E. Br. J. Pharmacol., 2000, 129, 501-8.
26. Cohen, Z., Bouchelet, I., Olivier, A., Villemure, J.G., Ball, R., Stanimirovic, D.B., Hamel, E. J. Cereb. Blood Flow Metab., 1999, 19, 908-17.
27. Adham, N., Borden, L.A., Schechter, L.E., Gustafson, E.L., Cochran, T.L., Vaysse, P.J., Weinshank, R.L., Branchek, T.A. Naunyn. Schmiedebergs Arch. Pharmacol., 1993, 348, 566-75.
28. Ma, Q.P. Neuroreport, 2001, 12, 1589-91.
29. Ramadan, N.M., Skljarevski, V., Phebus, L.A., Johnson, K.W. Cephalalgia, 2003, 2, 776-85.
30. Cohen, M.L., Schenck K. J. Pharmacol. Exp. Ther., 1999, 290, 935-9.
31. Cohen, M.L., Schenck, K. Br. J. Pharmacol., 2000, 131, 562-8.
32. Bergerot, A., Holland, P.R., Akerman, S., Bartsch, T., Ahn, A.H., Eur. J. Neurosci. 2006, 24, 1517-1534.
33. Mitsikostas, D.D. and Sanchez del Rio, M. Brain Res. Rev., 2001, 35, 20-35.
34. Phebus, L.A., Johnson, K.W., Zgombick, J.M., Gilbert, P.J., Van Belle, K., Mancuso, V., Nelson, D.L., Calligaro, D.O., Kiefer, A.D. Jr, Branchek, T.A., Flaugh, M.E. Life Sci., 1997, 61, 2117-2126.
35. Mitsikostas, D.D., Sanchez del Rio, M., Moskoswitz, M.A., Waeber, C. Eur. J. Pharmacol., 1999, 369, 211-277.
36. Mitsikostas, D.D., Sanchez del Rio, M., Waeber, C. Cephalalgia, 2002, 22, 384-394.
37. Katofiasc, M., Johnson, K., Phebus, L. Cephalalgia, 2000, 20, 419 [Abstract].
38. Shepheard, S., Edvinsson, L., Cumberbatch, M., Williamson, D., Mason, G., Webb, J., Boyce, S., Hill, R., Hargreaves, R. Cephalalgia, 1999, 19, 851-8.
39. Lucaites, V.L., Krushinski, J.H., Schaus, J.M., Audia, J.E., Nelson, D.L. Arch. Pharmacol., 2005, 371, 178-84.
40. Wainscott, D.B., Krushinski, J.H. Jr., Audia, J.E., Schaus, J.M., Zgombick, J.M., Lucaites, V.L., Nelson, D.L. Naunyn Schmiedebergs Arch. Pharmacol., 2005, 371, 169-77.
41. Xu, Y.C., Johnson, K.W., Phebus, L.A., Cohen, M., Nelson, D.L., Schenck, K., Walker, C.D., Fritz, J.E., Kaldor, S.W., LeTourneau, M.E., Murff, R.E., Zgombick, J.M., Calligaro, D.O., Audia, J.E., Schaus, J.M. J. Med. Chem., 2001, 44:4031-4.
42. Gossen, D., de Suray, J-M., Onkelinx, C. First human dose study with LY334370, a selective 5-HT1F agonist. Proceedings of the Migraine Trust Meeting, 1-4 September, London, 1998:64
43. Goldstein, D.J., Roon, K.I., Offen, W.W., Ramadan, N.M., Phebus, L.A., Johnson, K.W., Schaus, J.M., Ferrari, M.D. Lancet, 2001, 358, 1230-4.
44. Ferari, M.D., Roon, K.I., Lipton, R.B., Goadsby, P.J. Lancet, 2001, 358, 1668-1675.
45. Oldman, A. D., Smith, L.A., McQuay, H.J., Moore, A.R. Pain, 2002, 97, 247-257.
46. Ramadan, N.M., Skljarevski, V., Phebus, L.A., Johnson, K.W. Cephalalgia. 2003, 23, 776-85.
47. Thomas, D.R., Hagan, J.J. Curr. Drug Targets CNS Neurol. Disord., 2004, 3, 81-90.
48. Terron, J.A., Bouchelet, I., Hamel, E. Neurosci Lett., 2001, 302, 9-12.
49. Terron, J.A., Falcon-Neri, A. Br. J. Pharmacol., 1999, 127, 609-16.
50. Pouzet, B. CNS Drug Rev., 2002, 8, 90-100.
51. Terron, J.A. Europ. J. Pharmacol., 2002, 439, 1-11.